Wall Street Analysts Weigh In on Becton, Dickinson and Company's Prospects

💡 Becton, Dickinson and Company's stock has seen mixed opinions from Wall Street analysts.

The healthcare industry is facing significant headwinds, including rising costs and increased competition. Amidst this backdrop, Becton, Dickinson and Company ($BDX) has been a consistent performer, driven by its diversified portfolio of medical devices and pharmaceuticals.

Recent Earnings Performance Becton, Dickinson and Company's recent earnings report was met with a mixed reaction from analysts. While the company's revenue growth exceeded expectations, its profit margins were lower than anticipated. **Gross margin** compression due to higher **raw material costs** weighed on the bottom line.

Analyst Forecasts and Stock Price Wall Street analysts have a **buy** rating on Becton, Dickinson and Company, with an average **price target** of $285. However, some analysts have expressed concerns about the company's ability to sustain its growth momentum in the face of intense competition. $BDX has a **market capitalization** of around $70 billion, making it one of the largest healthcare companies in the world.

Valuation and Share Price Becton, Dickinson and Company's stock price has been relatively stable in recent months, with a **52-week range** of $240 to $270. The company's **price-to-earnings ratio** is around 25, which is slightly higher than the industry average.

What It Means for Investors Do you think Becton, Dickinson and Company's stock will hold above $250 in the next quarter? Share your view in the comments.